Harnessing dendritic cells for immunotherapy

Seminars in Immunology

Volumn 23, Issue 1, 2011, Pages 2-11

  Delamarre, Lélia ^a   Mellman Ira, I ^a  

^a GENENTECH INC   (United States)

Author keywords

Antigen presentation; Dendritic cells; Immunotherapy; Tolerance; Vaccines

Indexed keywords

CD11B ANTIGEN; CD1C ANTIGEN; CD40 ANTIGEN; DENDRITIC CELL VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; CD8+ T LYMPHOCYTE; CELL SUBPOPULATION; CROSS PRESENTATION; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; REVIEW; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGEN PRESENTATION; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY;

EID: 79952438607     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smim.2011.02.001     Document Type: Review

References (151)

1. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
2. Lanzavecchia A., Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001, 106:263-266.
3. Trombetta E.S., Mellman I. Cell biology of antigen processing in vitro and in vivo. Annual Review of Immunology 2005, 23:975-1028.
4. Faure-Andre G., Vargas P., Yuseff M.I., Heuze M., Diaz J., Lankar D., et al. Regulation of dendritic cell migration by CD74, the MHC class II-associated invariant chain. Science (New York, NY) 2008, 322:1705-1710.
5. Jiang A., Bloom O., Ono S., Cui W., Unternaehrer J., Jiang S., et al. Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation. Immunity 2007, 27:610-624.
6. Manicassamy S., Reizis B., Ravindran R., Nakaya H., Salazar-Gonzalez R.M., Wang Y.C., et al. Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science (New York, NY) 2010, 329:849-853.
7. Macagno A., Napolitani G., Lanzavecchia A., Sallusto F. Duration, combination and timing: the signal integration model of dendritic cell activation. Trends in Immunology 2007, 28:227-233.
8. Heath W.R., Carbone F.R. Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nature Immunology 2009, 10:1237-1244.
9. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
10. Palucka K., Banchereau J., Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010, 33:464-478.
11. Aarntzen E.H., Figdor C.G., Adema G.J., Punt C.J., de Vries I.J. Dendritic cell vaccination and immune monitoring. Cancer Immunology Immunotherapy 2008, 57:1559-1568.
12. McCurley N., Mellman I. Monocyte-derived dendritic cells exhibit increased levels of lysosomal proteolysis as compared to other human dendritic cell populations. PloS One 2010, 5:e11949.
13. Hawiger D., Inaba K., Dorsett Y., Guo M., Mahnke K., Rivera M., et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. The Journal of Experimental Medicine 2001, 194:769-779.
14. Bonifaz L., Bonnyay D., Mahnke K., Rivera M., Nussenzweig M.C., Steinman R.M. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. The Journal of Experimental Medicine 2002, 196:1627-1638.
15. Caminschi I., Lahoud M.H., Shortman K. Enhancing immune responses by targeting antigen to DC. European Journal of Immunology 2009, 39:931-938.
16. Platt C.D., Ma J.K., Chalouni C., Ebersold M., Bou-Reslan H., Carano R.A., et al. Mature dendritic cells use endocytic receptors to capture and present antigens. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:4287-4292.
17. Drutman S.B., Trombetta E.S. Dendritic cells continue to capture and present antigens after maturation in vivo. Journal of Immunology 2010, 185:2140-2146.
18. Dudziak D., Kamphorst A.O., Heidkamp G.F., Buchholz V.R., Trumpfheller C., Yamazaki S., et al. Differential antigen processing by dendritic cell subsets in vivo. Science (New York, NY) 2007, 315:107-111.
19. Hildner K., Edelson B.T., Purtha W.E., Diamond M., Matsushita H., Kohyama M., et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science (New York, NY) 2008, 322:1097-1100.
20. Klechevsky E., Morita R., Liu M., Cao Y., Coquery S., Thompson-Snipes L., et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008, 29:497-510.
21. Delamarre L., Pack M., Chang H., Mellman I., Trombetta E.S. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science (New York, NY) 2005, 307:1630-1634.
22. Delamarre L., Couture R., Mellman I., Trombetta E.S. Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis. The Journal of Experimental Medicine 2006, 203:2049-2055.
23. Amigorena S., Savina A. Intracellular mechanisms of antigen cross presentation in dendritic cells. Current Opinion in Immunology 2010, 22:109-117.
24. Norbury C.C., Hewlett L.J., Prescott A.R., Shastri N., Watts C. Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Immunity 1995, 3:783-791.
25. Norbury C.C., Chambers B.J., Prescott A.R., Ljunggren H.G., Watts C. Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. European Journal of Immunology 1997, 27:280-288.
26. Guermonprez P., Saveanu L., Kleijmeer M., Davoust J., Van Endert P., Amigorena S. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 2003, 425:397-402.
27. Houde M., Bertholet S., Gagnon E., Brunet S., Goyette G., Laplante A., et al. Phagosomes are competent organelles for antigen cross-presentation. Nature 2003, 425:402-406.
28. Ackerman A.L., Kyritsis C., Tampe R., Cresswell P. Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells. Nature Immunology 2005, 6:107-113.
29. Saveanu L., Carroll O., Weimershaus M., Guermonprez P., Firat E., Lindo V., et al. IRAP identifies an endosomal compartment required for MHC class I cross-presentation. Science (New York, NY) 2009, 325:213-217.
30. Shen L., Sigal L.J., Boes M., Rock K.L. Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo. Immunity 2004, 21:155-165.
31. Trombetta E.S., Ebersold M., Garrett W., Pypaert M., Mellman I. Activation of lysosomal function during dendritic cell maturation. Science (New York, NY) 2003, 299:1400-1403.
32. Savina A., Jancic C., Hugues S., Guermonprez P., Vargas P., Moura I.C., et al. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell 2006, 126:205-218.
33. Accapezzato D., Visco V., Francavilla V., Molette C., Donato T., Paroli M., et al. Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo. The Journal of Experimental Medicine 2005, 202:817-828.
34. Belizaire R., Unanue E.R. Targeting proteins to distinct subcellular compartments reveals unique requirements for MHC class I and II presentation. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:17463-17468.
35. Burgdorf S., Kautz A., Bohnert V., Knolle P.A., Kurts C. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science (New York, NY) 2007, 316:612-616.
36. Bonifaz L.C., Bonnyay D.P., Charalambous A., Darguste D.I., Fujii S., Soares H., et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. The Journal of Experimental Medicine 2004, 199:815-824.
37. Gil-Torregrosa B.C., Lennon-Dumenil A.M., Kessler B., Guermonprez P., Ploegh H.L., Fruci D., et al. Control of cross-presentation during dendritic cell maturation. European Journal of Immunology 2004, 34:398-407.
38. Cheong C., Choi J.H., Vitale L., He L.Z., Trumpfheller C., Bozzacco L., et al. Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody. Blood 2010, 116:3828-3838.
39. Bozzacco L., Trumpfheller C., Siegal F.P., Mehandru S., Markowitz M., Carrington M., et al. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:1289-1294.
40. Tsuji T., Matsuzaki J., Kelly M.P., Ramakrishna V., Vitale L., He L.Z., et al. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity. Journal of Immunology 2011, 186:1218-1227.
41. Singh R., Cresswell P. Defective cross-presentation of viral antigens in GILT-free mice. Science (New York, NY) 2010, 328:1394-1398.
42. Rodriguez A., Regnault A., Kleijmeer M., Ricciardi-Castagnoli P., Amigorena S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nature Cell Biology 1999, 1:362-368.
43. Giodini A., Rahner C., Cresswell P. Receptor-mediated phagocytosis elicits cross-presentation in nonprofessional antigen-presenting cells. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:3324-3329.
44. Ackerman A.L., Giodini A., Cresswell P. A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells. Immunity 2006, 25:607-617.
45. Touret N., Paroutis P., Terebiznik M., Harrison R.E., Trombetta S., Pypaert M., et al. Quantitative and dynamic assessment of the contribution of the ER to phagosome formation. Cell 2005, 123:157-170.
46. Lilley B.N., Ploegh H.L. A membrane protein required for dislocation of misfolded proteins from the ER. Nature 2004, 429:834-840.
47. Ye Y., Shibata Y., Yun C., Ron D., Rapoport T.A. A membrane protein complex mediates retro-translocation from the ER lumen into the cytosol. Nature 2004, 429:841-847.
48. Moore M.W., Carbone F.R., Bevan M.J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988, 54:777-785.
49. Boya P., Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene 2008, 27:6434-6451.
50. Schnurr M., Orban M., Robson N.C., Shin A., Braley H., Airey D., et al. ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II. Journal of Immunology 2009, 182:1253-1259.
51. Swiecki M., Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunological Reviews 2010, 234:142-162.
52. Reizis B, Bunin A, Ghosh HS, Lewis KL, Sisirak V. Plasmacytoid dendritic cells: recent progress and open questions. Annual Reviews in Immunology 2011; in press.
53. Sapoznikov A., Fischer J.A., Zaft T., Krauthgamer R., Dzionek A., Jung S. Organ-dependent in vivo priming of naive CD4+, but not CD8+, T cells by plasmacytoid dendritic cells. The Journal of Experimental Medicine 2007, 204:1923-1933.
54. Young L.J., Wilson N.S., Schnorrer P., Proietto A., Ten Broeke T., Matsuki Y., et al. Differential MHC class II synthesis and ubiquitination confers distinct antigen-presenting properties on conventional and plasmacytoid dendritic cells. Nature Immunology 2008, 9:1244-1252.
55. Villadangos J.A., Young L. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity 2008, 29:352-361.
56. Di Pucchio T., Chatterjee B., Smed-Sorensen A., Clayton S., Palazzo A., Montes M., et al. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nature Immunology 2008, 9:551-557.
57. Klechevsky E., Flamar A.L., Cao Y., Blanck J.P., Liu M., O'Bar A., et al. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood 2010, 116:1685-1697.
58. Matta B.M., Castellaneta A., Thomson A.W. Tolerogenic plasmacytoid DC. European Journal of Immunology 2010, 40:2667-2676.
59. Stoitzner P., Tripp C.H., Eberhart A., Price K.M., Jung J.Y., Bursch L., et al. Langerhans cells cross-present antigen derived from skin. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:7783-7788.
60. Flacher V., Tripp C.H., Stoitzner P., Haid B., Ebner S., Del Frari B., et al. Epidermal Langerhans cells rapidly capture and present antigens from C-type lectin-targeting antibodies deposited in the dermis. The Journal of Investigative Dermatology 2010, 130:755-762.
61. Romani N., Clausen B.E., Stoitzner P. Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin. Immunological Reviews 2010, 234:120-141.
62. Ritter U., Meissner A., Scheidig C., Korner H. CD8 alpha- and Langerin-negative dendritic cells, but not Langerhans cells, act as principal antigen-presenting cells in leishmaniasis. European Journal of Immunology 2004, 34:1542-1550.
63. Brewig N., Kissenpfennig A., Malissen B., Veit A., Bickert T., Fleischer B., et al. Priming of CD8+ and CD4+ T cells in experimental leishmaniasis is initiated by different dendritic cell subtypes. Journal of Immunology 2009, 182:774-783.
64. Bedoui S., Whitney P.G., Waithman J., Eidsmo L., Wakim L., Caminschi I., et al. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nature Immunology 2009, 10:488-495.
65. Henri S., Poulin L.F., Tamoutounour S., Ardouin L., Guilliams M., de Bovis B., et al. CD207+ CD103+ dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells. The Journal of Experimental Medicine 2010, 207:189-206.
66. MacDonald K.P., Munster D.J., Clark G.J., Dzionek A., Schmitz J., Hart D.N. Characterization of human blood dendritic cell subsets. Blood 2002, 100:4512-4520.
67. Robbins S.H., Walzer T., Dembele D., Thibault C., Defays A., Bessou G., et al. Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biology 2008, 9:R17.
68. Crozat K., Guiton R., Guilliams M., Henri S., Baranek T., Schwartz-Cornil I., et al. Comparative genomics as a tool to reveal functional equivalences between human and mouse dendritic cell subsets. Immunological Reviews 2010, 234:177-198.
69. den Haan J.M., Lehar S.M., Bevan M.J. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. The Journal of Experimental Medicine 2000, 192:1685-1696.
70. Schnorrer P., Behrens G.M., Wilson N.S., Pooley J.L., Smith C.M., El-Sukkari D., et al. The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:10729-10734.
71. Bachem A., Guttler S., Hartung E., Ebstein F., Schaefer M., Tannert A., et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+ CD141+ cells as homologues of mouse CD8+ dendritic cells. The Journal of Experimental Medicine 2010, 207:1273-1281.
72. Jongbloed S.L., Kassianos A.J., McDonald K.J., Clark G.J., Ju X., Angel C.E., et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. The Journal of Experimental Medicine 2010, 207:1247-1260.
73. Poulin L.F., Salio M., Griessinger E., Anjos-Afonso F., Craciun L., Chen J.L., et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. The Journal of Experimental Medicine 2010, 207:1261-1271.
74. Crozat K., Guiton R., Contreras V., Feuillet V., Dutertre C.A., Ventre E., et al. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. The Journal of Experimental Medicine 2010, 207:1283-1292.
75. Villadangos J.A., Shortman K. Found in translation: the human equivalent of mouse CD8+ dendritic cells. The Journal of Experimental Medicine 2010, 207:1131-1134.
76. Takeuchi A., Itoh Y., Takumi A., Ishihara C., Arase N., Yokosuka T., et al. CRTAM confers late-stage activation of CD8+ T cells to regulate retention within lymph node. Journal of Immunology 2009, 183:4220-4228.
77. Dorner B.G., Dorner M.B., Zhou X., Opitz C., Mora A., Guttler S., et al. Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells. Immunity 2009, 31:823-833.
78. Schulz O., Reis e Sousa C. Cross-presentation of cell-associated antigens by CD8alpha+ dendritic cells is attributable to their ability to internalize dead cells. Immunology 2002, 107:183-189.
79. Kamphorst A.O., Guermonprez P., Dudziak D., Nussenzweig M.C. Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes. Journal of Immunology 2010, 185:3426-3435.
80. Savina A., Peres A., Cebrian I., Carmo N., Moita C., Hacohen N., et al. The small GTPase Rac2 controls phagosomal alkalinization and antigen crosspresentation selectively in CD8(+) dendritic cells. Immunity 2009, 30:544-555.
81. Lindstedt M., Lundberg K., Borrebaeck C.A. Gene family clustering identifies functionally associated subsets of human in vivo blood and tonsillar dendritic cells. Journal of Immunology 2005, 175:4839-4846.
82. Klechevsky E., Liu M., Morita R., Banchereau R., Thompson-Snipes L., Palucka A.K., et al. Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines. Human Immunology 2009, 70:281-288.
83. Turley S.J., Inaba K., Garrett W.S., Ebersold M., Unternaehrer J., Steinman R.M., et al. Transport of peptide-MHC class II complexes in developing dendritic cells. Science (New York, NY) 2000, 288:522-527.
84. Chow A., Toomre D., Garrett W., Mellman I. Dendritic cell maturation triggers retrograde MHC class II transport from lysosomes to the plasma membrane. Nature 2002, 418:988-994.
85. Shin J.S., Ebersold M., Pypaert M., Delamarre L., Hartley A., Mellman I. Surface expression of MHC class II in dendritic cells is controlled by regulated ubiquitination. Nature 2006, 444:115-118.
86. van Niel G., Wubbolts R., Ten Broeke T., Buschow S.I., Ossendorp F.A., Melief C.J., et al. Dendritic cells regulate exposure of MHC class II at their plasma membrane by oligoubiquitination. Immunity 2006, 25:885-894.
87. De Gassart A., Camosseto V., Thibodeau J., Ceppi M., Catalan N., Pierre P., et al. MHC class II stabilization at the surface of human dendritic cells is the result of maturation-dependent MARCH I down-regulation. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:3491-3496.
88. Cella M., Engering A., Pinet V., Pieters J., Lanzavecchia A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 1997, 388:782-787.
89. Cella M., Salio M., Sakakibara Y., Langen H., Julkunen I., Lanzavecchia A. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. The Journal of Experimental Medicine 1999, 189:821-829.
90. Delamarre L., Holcombe H., Mellman I. Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. The Journal of Experimental Medicine 2003, 198:111-122.
91. den Haan J.M., Bevan M.J. Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo. The Journal of Experimental Medicine 2002, 196:817-827.
92. Datta S.K., Redecke V., Prilliman K.R., Takabayashi K., Corr M., Tallant T., et al. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. Journal of Immunology 2003, 170:4102-4110.
93. Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nature Medicine 2007, 13:552-559.
94. Palm N.W., Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunological Reviews 2009, 227:221-233.
95. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33:492-503.
96. Ahonen C.L., Doxsee C.L., McGurran S.M., Riter T.R., Wade W.F., Barth R.J., et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. The Journal of Experimental Medicine 2004, 199:775-784.
97. Longhi M.P., Trumpfheller C., Idoyaga J., Caskey M., Matos I., Kluger C., et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. The Journal of Experimental Medicine 2009, 206:1589-1602.
98. Trumpfheller C., Caskey M., Nchinda G., Longhi M.P., Mizenina O., Huang Y., et al. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:2574-2579.
99. Stahl-Hennig C., Eisenblatter M., Jasny E., Rzehak T., Tenner-Racz K., Trumpfheller C., et al. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathogens 2009, 5:e1000373.
100. Tewari K., Flynn B.J., Boscardin S.B., Kastenmueller K., Salazar A.M., Anderson C.A., et al. Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDEC-CSP in nonhuman primates. Vaccine 2010, 28:7256-7266.
101. Wille-Reece U., Flynn B.J., Lore K., Koup R.A., Miles A.P., Saul A., et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. The Journal of Experimental Medicine 2006, 203:1249-1258.
102. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nature Reviews 2008, 8:247-258.
103. Rajagopal D., Paturel C., Morel Y., Uematsu S., Akira S., Diebold S.S. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood 2010, 115:1949-1957.
104. Sikora A.G., Jaffarzad N., Hailemichael Y., Gelbard A., Stonier S.W., Schluns K.S., et al. IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. Journal of Immunology 2009, 182:7398-7407.
105. Blander J.M., Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006, 440:808-812.
106. Cho H.J., Takabayashi K., Cheng P.M., Nguyen M.D., Corr M., Tuck S., et al. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nature Biotechnology 2000, 18:509-514.
107. Wille-Reece U., Wu C.Y., Flynn B.J., Kedl R.M., Seder R.A. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. Journal of Immunology 2005, 174:7676-7683.
108. Beaudette T.T., Bachelder E.M., Cohen J.A., Obermeyer A.C., Broaders K.E., Frechet J.M., et al. In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines. Molecular Pharmaceutics 2009, 6:1160-1169.
109. Jerome V., Graser A., Muller R., Kontermann R.E., Konur A. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant. Journal of Immunotherapy 2006, 29:294-305.
110. Kaiser-Schulz G., Heit A., Quintanilla-Martinez L., Hammerschmidt F., Hess S., Jennen L., et al. Polylactide-coglycolide microspheres co-encapsulating recombinant tandem prion protein with CpG-oligonucleotide break self-tolerance to prion protein in wild-type mice and induce CD4 and CD8 T cell responses. Journal of Immunology 2007, 179:2797-2807.
111. Taylor P.R., Tsoni S.V., Willment J.A., Dennehy K.M., Rosas M., Findon H., et al. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nature Immunology 2007, 8:31-38.
112. Saijo S., Fujikado N., Furuta T., Chung S.H., Kotaki H., Seki K., et al. Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nature Immunology 2007, 8:39-46.
113. Robinson M.J., Osorio F., Rosas M., Freitas R.P., Schweighoffer E., Gross O., et al. Dectin-2 is a Syk-coupled pattern recognition receptor crucial for Th17 responses to fungal infection. The Journal of Experimental Medicine 2009, 206:2037-2051.
114. Saijo S., Ikeda S., Yamabe K., Kakuta S., Ishigame H., Akitsu A., et al. Dectin-2 recognition of alpha-mannans and induction of Th17 cell differentiation is essential for host defense against Candida albicans. Immunity 2010, 32:681-691.
115. Ni L., Gayet I., Zurawski S., Duluc D., Flamar A.L., Li X.H., et al. Concomitant activation and antigen uptake via human Dectin-1 results in potent antigen-specific CD8+ T cell responses. Journal of Immunology 2010, 185:3504-3513.
116. Carter R.W., Thompson C., Reid D.M., Wong S.Y., Tough D.F. Preferential induction of CD4+ T cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1. Journal of Immunology 2006, 177:2276-2284.
117. Carter R.W., Thompson C., Reid D.M., Wong S.Y., Tough D.F. Induction of CD8+ T cell responses through targeting of antigen to Dectin-2. Cellular Immunology 2006, 239:87-91.
118. Weck M.M., Appel S., Werth D., Sinzger C., Bringmann A., Grunebach F., et al. hDectin-1 is involved in uptake and cross-presentation of cellular antigens. Blood 2008, 111:4264-4272.
119. Bennett S.R., Carbone F.R., Karamalis F., Flavell R.A., Miller J.F., Heath W.R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998, 393:478-480.
120. Ridge J.P., Di Rosa F., Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998, 393:474-478.
121. Schoenberger S.P., Toes R.E., van der Voort E.I., Offringa R., Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998, 393:480-483.
122. Schulz O., Edwards A.D., Schito M., Aliberti J., Manickasingham S., Sher A., et al. CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity 2000, 13:453-462.
123. Sanchez P.J., McWilliams J.A., Haluszczak C., Yagita H., Kedl R.M. Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo. Journal of Immunology 2007, 178:1564-1572.
124. McWilliams J.A., Sanchez P.J., Haluszczak C., Gapin L., Kedl R.M. Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity. Vaccine 2010, 28:1468-1476.
125. Anolik J., Looney R.J., Bottaro A., Sanz I., Young F. Down-regulation of CD20 on B cells upon CD40 activation. European Journal of Immunology 2003, 33:2398-2409.
126. Chen Y., Chen J., Xiong Y., Da Q., Xu Y., Jiang X., et al. Internalization of CD40 regulates its signal transduction in vascular endothelial cells. Biochemical and Biophysical Research Communications 2006, 345:106-117.
127. Schjetne K.W., Fredriksen A.B., Bogen B. Delivery of antigen to CD40 induces protective immune responses against tumors. Journal of Immunology 2007, 178:4169-4176.
128. Barr T.A., McCormick A.L., Carlring J., Heath A.W. A potent adjuvant effect of CD40 antibody attached to antigen. Immunology 2003, 109:87-92.
129. Lee H.K., Iwasaki A. Innate control of adaptive immunity: dendritic cells and beyond. Seminars in Immunology 2007, 19:48-55.
130. Park B., Brinkmann M.M., Spooner E., Lee C.C., Kim Y.M., Ploegh H.L. Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nature Immunology 2008, 9:1407-1414.
131. Ewald S.E., Lee B.L., Lau L., Wickliffe K.E., Shi G.P., Chapman H.A., et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 2008, 456:658-662.
132. Sepulveda F.E., Maschalidi S., Colisson R., Heslop L., Ghirelli C., Sakka E., et al. Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells. Immunity 2009, 31:737-748.
133. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annual Review of Immunology 2003, 21:685-711.
134. Probst H.C., Lagnel J., Kollias G., van den Broek M. Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. Immunity 2003, 18:713-720.
135. Yamazaki S., Iyoda T., Tarbell K., Olson K., Velinzon K., Inaba K., et al. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. The Journal of Experimental Medicine 2003, 198:235-247.
136. Yamazaki S., Bonito A.J., Spisek R., Dhodapkar M., Inaba K., Steinman R.M. Dendritic cells are specialized accessory cells along with TGF- for the differentiation of Foxp3+ CD4+ regulatory T cells from peripheral Foxp3 precursors. Blood 2007, 110:4293-4302.
137. Mukhopadhaya A., Hanafusa T., Jarchum I., Chen Y.G., Iwai Y., Serreze D.V., et al. Selective delivery of beta cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:6374-6379.
138. Coombes J.L., Siddiqui K.R., Arancibia-Carcamo C.V., Hall J., Sun C.M., Belkaid Y., et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. The Journal of Experimental Medicine 2007, 204:1757-1764.
139. Sun C.M., Hall J.A., Blank R.B., Bouladoux N., Oukka M., Mora J.R., et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. The Journal of Experimental Medicine 2007, 204:1775-1785.
140. Guilliams M., Crozat K., Henri S., Tamoutounour S., Grenot P., Devilard E., et al. Skin-draining lymph nodes contain dermis-derived CD103(-) dendritic cells that constitutively produce retinoic acid and induce Foxp3(+) regulatory T cells. Blood 2010, 115:1958-1968.
141. Wang L., Pino-Lagos K., de Vries V.C., Guleria I., Sayegh M.H., Noelle R.J. Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+ CD4+ regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:9331-9336.
142. Irla M., Kupfer N., Suter T., Lissilaa R., Benkhoucha M., Skupsky J., et al. MHC class II-restricted antigen presentation by plasmacytoid dendritic cells inhibits T cell-mediated autoimmunity. The Journal of Experimental Medicine 2010, 207:1891-1905.
143. Laffont S., Siddiqui K.R., Powrie F. Intestinal inflammation abrogates the tolerogenic properties of MLN CD103+ dendritic cells. European Journal of Immunology 2010, 40:1877-1883.
144. Latchman Y.E., Liang S.C., Wu Y., Chernova T., Sobel R.A., Klemm M., et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:10691-10696.
145. Liang S., Alard P., Zhao Y., Parnell S., Clark S.L., Kosiewicz M.M. Conversion of CD4+ CD25- cells into CD4+ CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus. The Journal of Experimental Medicine 2005, 201:127-137.
146. Probst H.C., McCoy K., Okazaki T., Honjo T., van den Broek M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nature Immunology 2005, 6:280-286.
147. Schildknecht A., Brauer S., Brenner C., Lahl K., Schild H., Sparwasser T., et al. FoxP3+ regulatory T cells essentially contribute to peripheral CD8+ T-cell tolerance induced by steady-state dendritic cells. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:199-203.
148. Fukaya T., Takagi H., Sato Y., Sato K., Eizumi K., Taya H., et al. Crucial roles of B7-H1 and B7-DC expressed on mesenteric lymph node dendritic cells in the generation of antigen-specific CD4+ Foxp3+ regulatory T cells in the establishment of oral tolerance. Blood 2010, 116:2266-2276.
149. Mellman I., Clausen B.E. Immunology. Beta-catenin balances immunity. Science (New York, NY) 2010, 329:767-769.
150. Reis e Sousa C. Toll-like receptors and dendritic cells: for whom the bug tolls. Seminars in immunology 2004, 16:27-34.
151. Luber C.A., Cox J., Lauterbach H., Fancke B., Selbach M., Tschopp J., et al. Quantitative proteomics reveals subset-specific viral recognition in dendritic cells. Immunity 2010, 32:279-289.